Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Organisation › Details

Corimmun GmbH

CorImmun's lead compound, COR-1, is a small cyclic peptide currently in early clinical development for the treatment of heart failure. COR-1 has been shown in preclinical studies to improve heart function by decreasing autoimmune, beta 1 receptor-simulating antibody effects. Corimmun, was founded in 2006. It succeeded in combining two outstanding cardiovascular "GO-Bio" projects from the Universities of Würzburg and Tübingen in one business start-up. GO-Bio is a public grant programme of the Federal Ministry of Education and Research (BMBF), which intends to foster entrepreneurship in the life sciences sector. Corimmun thereby qualified for seed funding from High-Tech Gründerfonds, Bayernkapital and Bio-M. With three financing rounds (2006: Seed, 2008: Series A, 2010: Series B), Corimmun was able to obtain total equity of approx. EUR 13.5 million. MIG was the lead investor in rounds A and B. The financing rounds were supported by the following Co-investors: KfW (Bankengruppe), High-Tech Gruenderfonds, Bayern Kapital GmbH and Bio-M AG, Munich Biotech Development. Corimmun also received public funding as a "lighthouse project" in the "m4 Munich Leading-Edge Cluster" Programme, which is another BMBF public grant programme. *

 

Period Start 2006-01-01 established
  Group Johnson & Johnson (JnJ) (Group)
Products Industry cardiovascular drug
  Industry 2 COR-1
     
Region Region Martinsried
  Country Germany
  Street 29a Lochhamer Str.
  City 82152 Martinsried
  Tel +49-89-8565-2010
    Address record changed: 2018-07-24
     
Basic data Employees n. a.
     
    * Document for �About Section�: High-Tech Gründerfonds Management GmbH. (7/26/12). "Press Release: Investors Realize Exit via Trade Sale of Portfolio Company CorImmun GmbH". Neuss.
     
   
Record changed: 2018-10-31

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Johnson & Johnson (JnJ) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top